There is a moment in every serious company’s life where the science stops whispering and starts clearing its throat. Third Arc Bio just hit that moment. $52M in Series A extension capital does not...
There is a moment in every serious company’s life where the science stops whispering and starts clearing its throat. Third Arc Bio just hit that moment. $52M in Series A extension capital does not show up to be polite. It shows up when the work is already loud, when conviction has receipts, when the arc you are drawing bends toward something real. This round, announced Feb 3, 2026, takes total capital to $217M and signals that the story has moved from promise to pressure.
Third Arc Bio was founded in 2022 by Sanjaya Singh, PhD, with a simple but dangerous idea: if you are going to engage the immune system, you better know exactly who you are talking to and when. Multifunctional antibodies that form precise immune synapses are not a slogan. They are architecture. ARCStim in oncology. ARCTag in immunology and inflammation. 2 platforms built to do something most talk about and few deliver, activating or inhibiting T cells without collateral damage.
Andreessen Horowitz led this extension as a new investor, and that matters. When a16z shows up late, it is usually because the data walked into the room first. Omega Funds doubled down as a founding investor, joined by Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, abrdn Inc., T. Rowe Price Associates, Marshall Wace, Hillhouse Investment, AbbVie Ventures, Galapagos NV, and Alderline Group. That is not a crowd chasing noise. That is capital following signal.
Peter F. Lebowitz, MD, PhD, CEO and CMO, brings a clinical compass forged by 13 major drug approvals and decades of oncology scar tissue. Sanjaya Singh, PhD, brings the scientific instincts of someone who has invented therapies physicians already trust. Joe Erhardt, PhD, CRDO, brings development muscle shaped by 6 approved drugs and a career translating discovery into medicine. Collectively, this team has helped deliver more than 35 approved therapies. Experience like that does not blink under pressure. It applies it.
The lead program, ARC101, is already in Phase 1 dose escalation for CLDN6 positive solid tumors, with the first patient dosed in Mar 2025. High specificity. No off target binding to other claudins. Meanwhile, the immunology and inflammation portfolio accelerates in parallel, powered by capital that understands timelines, risk curves, and why patience paired with urgency wins.
Third Arc Bio is not named for theatrics. Every arc has tension. Every arc needs structure. This one is being drawn by people who know that progress is rarely linear, that silence between milestones matters, and that when science and capital finally sync their tempo, the rest of the industry starts listening a little harder.